Congenital adrenal hyperplasia
May 09, 2025
Congenital Adrenal Hyperplasia Treatment in Transition: Innovations, Setbacks, and Strategic Shifts Shaping the Market
Congenital Adrenal Hyperplasia (CAH) is a group of inherited genetic disorders that affect adrenal gland function, most commonly caused by a deficiency in the enzyme 21-hydroxylase. This enzyme deficiency disrupts the production of cortisol and often aldosterone, leading to hormonal imbalances and excess androgen p...
Read More...
Dec 17, 2024
FDA Approves Neurocrine’s CRENESSITY for Congenital Adrenal Hyperplasia; Checkpoint’s UNLOXCYT Approved; MAIA’s THIO Gets Rare Pediatric Disease Designation; JEMPERLI Receives Breakthrough Therapy for Rectal Cancer; Galderma’s NEMLUVIO Approved for Atopic Dermatitis.
Neurocrine Announces FDA Approval of CRENESSITY for Congenital Adrenal Hyperplasia Neurocrine Biosciences, Inc. announced that the FDA has approved CRENESSITY™ (crinecerfont) as an adjunctive treatment to glucocorticoid replacement for controlling androgens in adult and pediatric patients aged four years and old...
Read More...
Aug 15, 2022
Will The Emerging Pipeline Address The Congenital Adrenal Hyperplasia Treatment Puzzle?
Congenital adrenal hyperplasia (CAH) is a rare inherited autosomal recessive disorder defined by a lack of one of the enzymes required to produce specific hormones. In the United States and Europe, the most prevalent type of CAH, 21 hydroxylase deficiency, affects around 1:10,000 to 1:15,000 people. The estimated C...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
